Next week, on January 22nd, an FDA Advisory Committee will review eteplirsen for potential approval and use within our Duchenne community.
The Duchenne community is joining forces in a show of strength to demonstrate to the FDA our community’s support for our robust therapeutic pipeline. All Duchenne community members are encouraged to attend the Advisory Committee meeting to show our community’s support of eteplirsen. The Duchenne community is known for 'showing up’ and we are again seeking to make history by doing so in record numbers to once again demonstrate the power of our Duchenne community.
Please consider joining us:
As Duchenne community members from across the globe make plans to get to the FDA in January, let’s also ensure that the FDA’s campus is filled with a powerful showing of support from our local Duchenne community!